Suicide mortality in metabolic dysfunction-associated liver diseases: a nationwide cohort study.

Authors

Chaiho Jeong, Kyu-Na Lee, Dae Jong Oh, Soon Kyu Lee, Chang Wook Kim, Kyungdo Han, Mee Kyoung Kim

Published in

Annals of medicine. Volume 58. Issue 1. Pages 2707708. Epub Aug 07, 2026.

Abstract

Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction-associated alcohol-related liver disease (MetALD) are becoming more recognised as common chronic liver conditions. Despite this, their relationship with suicide mortality has not been thoroughly investigated.
We conducted a nationwide population-based cohort study involving 4,348,487 Korean adults who underwent health screening in 2012. Participants were categorised into four groups based on fatty liver index, metabolic risk factors, and alcohol consumption: no steatotic liver disease (no SLD, n = 3,794,988), MASLD (n = 450,600), MetALD (n = 81,079), and alcohol-associated liver disease (ALD, n = 21,820). We utilised Cox proportional hazards models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs) for suicide mortality. Participants were followed until death or the conclusion of the study period.
During a median follow-up of 9.2 years, 9,830 participants died by suicide. Compared to individuals without SLD, the adjusted HRs for suicide mortality were significantly elevated across all SLD subtypes: 1.20 (95% CI: 1.12-1.29) for MASLD, 1.39 (95% CI: 1.23-1.57) for MetALD, and 1.39 (95% CI: 1.11-1.74) for ALD. A dose-dependent increase in suicide mortality was observed with higher levels of alcohol consumption. Even among individuals with low alcohol intake, SLD remained associated with a higher risk of suicide compared to non-SLD (HR: 1.24; 95% CI: 1.15-1.33).
Both MASLD and MetALD were associated with a higher risk of suicide mortality. These findings highlight the combined effects of metabolic dysfunction and alcohol use on suicide risk within these populations.

PMID:
42566291
Bibliographic data and abstract were imported from PubMed on 08 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.